PETALING JAYA: More Hepatitis C patients will soon be able to afford treatment, thanks to the decision by a US pharmaceutical company to expand its generic licensing agreement to Malaysia.
Gilead Science, an American research-based biopharmaceutical company, announced its decision on Aug 24 to expand its HIV and Hepatitis C generic licensing agreement to Malaysia, Thailand, Ukraine and Belarus.
